Clinical outcomes of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil or regorafenib in metastatic colorectal cancer: a multicenter cohort study

20260 citationsJournal Articlegold Open Access

Authors

F. Moik · Medical University of Graz

F. Huemer · Paracelsus Medical University

B. Doleschal · Krankenhaus der Elisabethinen

H. Taghizadeh · Universitätsklinikum St. Pölten

P. Reimann · Landeskrankenhaus Feldkirch

S.M. Kostmann · Medical University of Graz

L. Wagner ·

Abstract

In this large real-world cohort of patients with mCRC, FTD-TPI + bevacizumab was associated with improved PFS and DCR compared with FTD-TPI or regorafenib, with consistent benefit across most molecular subgroups, including KRAS<sup>G12</sup> mutations.

Topics & Keywords

Colorectal Cancer Treatments and Studies Advanced Breast Cancer Therapies Oral health in cancer treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: ESMO Open

Volume 11, Issue 4, pp. 106907-106907

DOI: 10.1016/j.esmoop.2026.106907

Field-Weighted Citation Impact: 0.00